Peptide Biologix
Compound index
The atlas

Kisspeptin-10 Technical Specification Sheet

Reproductive / Melanocortin · MW 1302.45 g/mol · KISS1 metastasis suppressor, Metastin(45-54) · C-terminal active decapeptide fragment of kisspeptin-54 and GPR54 (KISS1R) agonist regulating hypothalamic GnRH release; kisspeptin-10 remains listed in Category 2 (503A) on FDA’s compounding bulk drug substances page current as of April 22, 2026.

Engraved study of a small branching coral skeleton with fine surface ridges
Plate 16Kisspeptin-10
Primary Amino Acid Sequence Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂

Molecular Properties

Parameter Value
Chemical Name Metastin (45-54) / Kisspeptin-10
Amino Acid Sequence Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂
Molecular Formula C₆₃H₈₃N₁₇O₁₄
Molecular Weight 1302.45 g/mol
CAS Number 374675-21-5
Sequence Length 10 amino acids (C-terminal decapeptide)
Receptor Target KISS1R (GPR54)

Physical Properties

Property Specification
Appearance White to off-white lyophilized powder
Solubility Soluble in sterile water, PBS (pH 7.0-7.4), or 0.9% saline at ≥1 mg/mL
pH (1% solution) 5.5 - 7.0
Hygroscopicity Moderate; store in desiccated environment
Solution Stability Stable at 4°C for 48-72 hours after reconstitution

Analytical Specifications

Test Specification
HPLC Purity ≥98.0%
Mass Spectrometry Confirmed [M+H]⁺ = 1302.45 ± 0.5 Da
Peptide Content ≥95% (by amino acid analysis)
Endotoxin Level <1.0 EU/mg
Acetate Content ≤5%
TFA Content ≤0.1%
Water Content ≤8% (Karl Fischer)

Storage Parameters

Condition Specification
Lyophilized Storage -20°C to -80°C, desiccated
Lyophilized Shelf Life 24-36 months when stored properly
Reconstituted Storage 2-8°C for up to 14 days; -20°C for up to 3 months
Analytical Stock Preparation Dissolve in sterile water or PBS (pH 7.0-7.4) with gentle vortexing for 30-60 seconds
Freeze-Thaw Cycles Avoid multiple cycles; single-use aliquoting recommended
Light Sensitivity Protect from direct light; store in amber vials

In Vitro & Preclinical Model Concentrations

Literature summary of published study doses, routes, and schedules.
Experimental Model Published Concentration / Regimen Exposure Schedule Administration Context
In Vitro Cell Studies 10-1000 nM Single or repeated exposure Culture media
Small Animal Models (Rodent) 0.1-10 nmol/animal (50-500 μg/kg) Once daily to BID IP, SC, IV in rodent models
GnRH Stimulation Studies (Animal) 1-10 nmol/kg Acute or pulsatile IV bolus in animal models
Reproductive Axis Research (Rodent) 0.5-5 nmol/kg Daily for 7-14 days SC in rodent models

Note: Concentrations and animal regimens summarized above are for research reference only. Kisspeptin-10 is intended strictly for in vitro and animal research purposes and is not approved for human therapeutic use.

Key Research Studies

Literature summary of published study doses, routes, and schedules.
Year Study Focus Key Findings
2005 GPR54 receptor activation and GnRH secretion Demonstrated that kisspeptin-10 is the minimal active fragment capable of stimulating GnRH neurons and triggering LH release with EC₅₀ ~1 nM at GPR54 receptor
2011 Hypothalamic-pituitary-gonadal axis regulation Investigational IV administration of kisspeptin-10 (0.01-1 nmol/kg) dose-dependently increased LH and FSH in clinical research subjects; effects blocked by GnRH antagonists
2015 Metabolic and reproductive integration Kisspeptin-10 infusion modulated both reproductive hormone secretion and metabolic parameters; demonstrated cross-talk between energy balance and fertility pathways
2018 Structure-activity relationship analysis C-terminal Arg-Phe-NH₂ motif identified as critical for receptor binding; N-terminal modifications reduced potency by 10-100 fold compared to native kisspeptin-10

Mechanism of Action

Biological Pathway Description
Receptor Binding High-affinity agonist at KISS1R (GPR54), a Gq-coupled GPCR expressed on GnRH neurons
Signal Transduction Activates phospholipase C → IP₃/DAG pathway → Ca²⁺ mobilization → neuronal depolarization
GnRH Release Direct stimulation of GnRH neurons in arcuate nucleus and AVPV; triggers GnRH pulsatile secretion
Downstream Effects LH and FSH release from pituitary gonadotrophs; subsequent gonadal steroidogenesis
Half-Life ~30-40 minutes (IV); rapid degradation by peptidases

Regulatory & Compounding Status (April 2026)

On FDA’s page on bulk drug substances used in compounding, current as of April 22, 2026, kisspeptin-10 is listed in Category 2 under 503A (bulk drug substances that raise significant safety risks in compounding). Kisspeptin-10 is not approved by the U.S. FDA for human or veterinary therapeutic use. This monograph is intended strictly for laboratory research.

External References

  1. National Center for Biotechnology Information. PubChem Compound Summary for Kisspeptin-10. https://pubchem.ncbi.nlm.nih.gov/compound/Kisspeptin-10
  2. Seminara SB, et al. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003;349(17):1614-27. https://www.nejm.org/doi/full/10.1056/NEJMoa035322
  3. Jayasena CN, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest. 2014;124(8):3667-77. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109546/